Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: Results of the "THERAPY"phase 1-2 trial

Oncotarget

Volumn 6, Issue 14, 2015, Pages 12796-12808

  Assenat, Eric ^a,b   Azria, David ^b,c,d   Mollevi, Caroline ^b   Guimbaud, Rosine ^e   Tubiana Mathieu, Nicole ^f   Smith, Denis ^g   Delord, Jean Pierre ^h   Samalin, Emmanuelle ^b   Portales, Fabienne ^b   Larbouret, Christel ^b,c,d   Robert, Bruno ^b,c,d   Bibeau, Frédéric ^b   Bleuse, Jean Pierre ^b   Crapez, Evelyne ^b   Ychou, Marc ^a,b,c,d   Pèlegrin, André ^b,c,d  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^d UNIV MONTPELLIER   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Antibody combination; Cetuximab; Pancreatic cancer; Phase 1 2; Trastuzumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIIA; FLUOROURACIL; GEMCITABINE; K RAS PROTEIN; OXALIPLATIN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; EGFR PROTEIN, HUMAN;

ABDOMINAL PAIN; ACNE; ADJUVANT THERAPY; ADULT; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRY SKIN; EDEMA; EMBOLISM; FEMALE; GENE EXPRESSION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PARONYCHIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; VOMITING; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PROCEDURES; SALVAGE THERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CETUXIMAB; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SALVAGE THERAPY; TRASTUZUMAB;

EID: 84930017906     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3473     Document Type: Article

References (39)

1. National Cancer Institute. Cancer of the Pancreas-SEER Stat Fact Sheets. 2010. Available from: http://seer.cancer.gov/statfacts/html/pancreas.html.
2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-2413.
3. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011; 364:1817-1825.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691-1703.
5. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels J a. C. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002; 87:161-167.
6. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004; 22:1430-1438.
7. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem J-L, Verslype C, Scheithauer W, Shang A, Cosaert J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009; 27:2231-2237.
8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25:1960-1966.
9. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, et al. Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol. 2010; 28:3605-3610.
10. Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A, Smith RC. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol. 2005; 29:1125-1134.
11. Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, et al. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med. 2003; 11:305-309.
12. Dugan MC, Dergham ST, Kucway R, Singh K, Biernat L, Du W, Vaitkevicius VK, Crissman JD, Sarkar FH. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas. 1997; 14:229-236.
13. Chou A, Waddell N, Cowley MJ, Gill AJ, Chang DK, Patch A-M, Nones K, Wu J, Pinese M, Johns AL, et al. Clinical and molecular characterization of HER2 amplified pancreatic cancer. Genome Med. 2013 August 31; 5:78.
14. Lurje G, Lenz H-J. EGFR Signaling and Drug Discovery. Oncology. 2009; 77:400-410.
15. Yamanaka Y, Friess H, Kobrin MS, Büchler M, Kunz J, Beger HG, Korc M. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol. 1993; 24:1127-1134.
16. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 2004; 22:706-712.
17. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL. Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial. J Clin Oncol. 2004; 22:2610-2616.
18. Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008; 9:39-44.
19. Larbouret C, Robert B, Navarro-Teulon I, Thèzenas S, Ladjemi M-Z, Morisseau S, Campigna E, Bibeau F, Mach J-P, Pèlegrin A, et al. In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas. Clin Cancer Res. 2007; 13:3356-3362.
20. Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach J-P, Pèlegrin A, Azria D. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol. 2010; 21:98-103.
21. Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach J-P, Azria D, Robert B, Pèlegrin A. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Neoplasia N Y NY. 2012;14:121.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
23. Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, et al. Sorafenib and irinotecan (NEXIRI) as second-or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer. 2014; 110:1148-1154.
24. Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, et al. Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial. The Oncologist. 2011; 16:1557-1564.
25. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, et al. Impact of Fc{gamma}RIIa-Fc{gamma} RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009; 27:1122-1129.
26. De P, Hasmann M, Leyland-Jones B. Molecular determinants of trastuzumab efficacy: What is their clinical relevance?. Cancer Treat Rev. 2013; 39:925-934.
27. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011; 47:1676-1681.
28. Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul J-L, Cattan S, Phelip J-M, Hammel P, Chauffert B, et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010; 59:1527-1534.
29. Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, Bono JD, Soria J-C, Kaye S, Paoletti X. Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?. J Clin Oncol. 2011; 29:1728-1735.
30. Paoletti X, Le Tourneau C, Collette L, Rizzo E, Lacombe D, Olmos D, Siu L, Percy Y, Seymour L, Kaye SB, et al. Towards new methods for the determination of doselimiting toxicities and the assessment of the recommended dose for further studies of non-cytotoxic agents. Abstract presented at the European Cancer Congress in Amsterdam, Netherlands. Eur J Cancer. 2013; 49:S5.
31. Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, et al. Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer. J Clin Oncol. 2012; 30:1505-1512.
32. Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, et al. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2013. Available from: http://link.springer.com/10.1007/s10637-013-9956-5.
33. Stepanski EJ, Reyes C, Walker MS, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller PJE, Houts AC, Schwartzberg LS. The Association of Rash Severity With Overall Survival: Findings from Patients Receiving Erlotinib for Pancreatic Cancer in the Community Setting. Pancreas January 2013. 2013; 42:32-36.
34. Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, et al. KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy. Oncology. 2011; 81:3-8.
35. Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, et al. Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. J Clin Oncol. 2012; 30:2861-2868.
36. Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer. 2013; 132:236-245.
37. Takata T, Tarutani M, Zouboulis CC, Sano S. Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption. J Dermatol Sci. 2012; 66:165-168.
38. Ho-Pun-Cheung A, Bazin H, Gaborit N, Larbouret C, Garnero P, Assenat E, Castan F, Bascoul-Mollevi C, Ramos J, Ychou M, et al. Quantification of HER Expression and Dimerization in Patients' Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer. PLoS ONE. 2012; 7:e37065.
39. Kordes S, Richel DJ, Klumpen H-J, Weterman MJ, Stevens AJWM, Wilmink JW. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Invest New Drugs. 2013; 31:85-91.